REFERENCES
Ayerbe, L., Risco, C., & Ayis, S. (2020). The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis . doi:10.1007/s11239-020-02162-z
Bertini, S., Risi, G., Guerrini, M., Carrick, K., Szajek, A. Y., & Mulloy, B. (2017). Molecular Weights of Bovine and Porcine Heparin Samples: Comparison of Chromatographic Methods and Results of a Collaborative Survey. Molecules, 22 (7). doi:10.3390/molecules22071214
Caly, L., Druce, J., Roberts, J., Bond, K., Tran, T., Kostecki, R., . . . Catton, M. G. (2020). Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust, 212 (10), 459-462. doi:10.5694/mja2.50569
Cassinelli, G., Torri, G., & Naggi, A. (2020). Non-Anticoagulant Heparins as Heparanase Inhibitors. Adv Exp Med Biol, 1221 , 493-522. doi:10.1007/978-3-030-34521-1_20
Frohlich, E., Mercuri, A., Wu, S., & Salar-Behzadi, S. (2016). Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds. Front Pharmacol, 7 , 181. doi:10.3389/fphar.2016.00181
Guimond, S., Mycroft-West, C., Gandhi, N., Tree, J., Buttigieg, K., Coombes, N., . . . Turnbull, J. (2020). Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus. bioRxiv. 2020.06.24.169334 .
Hirsh, J., Anand, S. S., Halperin, J. L., and Fuster, V. (2001). Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation, 103 (24), 2994-3018.
Hogwood, J., Mulloy, B., & Gray, E. (2017). Precipitation and Neutralization of Heparin from Different Sources by Protamine Sulfate.Pharmaceuticals (Basel), 10 (3). doi:10.3390/ph10030059
Johnson, R. M., Dahlgren, L., Siegfried, B. D., & Ellis, M. D. (2013). Acaricide, fungicide and drug interactions in honey bees (Apis mellifera). PLoS One, 8 (1), e54092. doi:10.1371/journal.pone.0054092
Keire, D. A., Mulloy, B., Chase, C., Al-Hakim, A., Cairatti, D., Gray, E., . . . Soares, M. (2015). Diversifying the global heparin supply chain reintroduction of bovine heparin in the United States?Pharmaceutical Technology 39 , 2-8.
Kollias, A., Kyriakoulis, K. G., Dimakakos, E., Poulakou, G., Stergiou, G. S., & Syrigos, K. (2020). Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action.Br J Haematol, 189 (5), 846-847. doi:10.1111/bjh.16727
Lewandowski, K., Xu, Y., Pullan, S. T., Lumley, S. F., Foster, D., Sanderson, N., . . . Matthews, P. C. (2019). Metagenomic Nanopore Sequencing of Influenza Virus Direct from Clinical Respiratory Samples.J Clin Microbiol, 58 (1). doi:10.1128/JCM.00963-19
Lindahl, U., & Li, J. P. (2020). Heparin - an old drug with multiple potential targets in Covid-19 therapy. J Thromb Haemost . doi:10.1111/jth.14898
Liu, L., Chopra, P., Li, X., Wolfert, M. A., Tompkins, S. M., & Boons, G.-J. (2020). SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner. bioRxiv2020.2005.2010.087288. doi:10.1101/2020.05.10.087288
Mulloy, B., & Hogwood, J. (2015). Chromatographic molecular weight measurements for heparin, its fragments and fractions, and other glycosaminoglycans. Methods Mol Biol, 1229 , 105-118. doi:10.1007/978-1-4939-1714-3_11
Mulloy, B., Hogwood, J., Gray, E., Lever, R., & Page, C. P. (2016). Pharmacology of Heparin and Related Drugs. Pharmacol Rev, 68 (1), 76-141. doi:10.1124/pr.115.011247
Mycroft-West, C., Su, D., Elli, S., Li, Y., Guimond, S., Miller, G., . . . Skidmore, M. (2020a). The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. bioRxiv 2020.2002.2029.971093. doi:10.1101/2020.02.29.971093
Mycroft-West, C. J., Su, D., Pagani, I., Rudd, T. R., Elli, S., Guimond, S. E., . . . Skidmore, M. A. (2020b). Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin. JbioRxiv 2020.2004.2028.066761. doi:10.1101/2020.04.28.066761
Partridge, L. J., Green, L. R., & Monk, P. N. (2020). Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line. bioRxiv 2020.2005.2021.107870. doi:10.1101/2020.05.21.107870
Project. (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.https://www.R-project.org/.
Schaefer, I. M., Padera, R. F., Solomon, I. H., Kanjilal, S., Hammer, M. M., Hornick, J. L., & Sholl, L. M. (2020). In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. Mod Pathol . doi:10.1038/s41379-020-0595-z
Tandon, R., Sharp, J. S., Zhang, F., Pomin, V. H., Ashpole, N. M., Mitra, D., . . . Linhardt, R. J. (2020). Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. bioRxiv 2020.2006.2008.140236. doi:10.1101/2020.06.08.140236
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost, 18 (5), 1094-1099. doi:10.1111/jth.14817
Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 18 (4), 844-847. doi:10.1111/jth.14768
U.S.P. United States Pharmacopeia. https://www.usp.org/, General Chapter 208 .
van Haren, F., Page, C. P., Laffey, M. D., Artigas, A., Camprubi-Rimblas, M., Nunes, Q., . . . Dixon, B. (2020). Nebulised heparin as a treatment for COVID-19: scientific rationale and a global call for randomised evidence. Critical Care, in press .